MedTrace Logo

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

NCT03881774 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-03-21

No results posted yet for this study

Summary

Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fail to preparation for autologous CAR-T cells

Conditions

  • Refractory
  • Relapsed
  • B Cell Lymphoma
  • B Cell Leukemia

Interventions

BIOLOGICAL

CAR-T cells

collecting cord blood for CAR-T cells culture; three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CAR-T cell with a dose of 0.5-3x106/kg

Sponsors & Collaborators

  • Henan Hualong Biotechnology Company

    collaborator UNKNOWN

  • Henan Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Yongping Song, Dr. · Henan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-27
Primary Completion
2021-01-31
Completion
2022-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03881774 on ClinicalTrials.gov